Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Modern Treatment of Schizophrenia

neuroscienceCME Multimedia Snack

Premiere Date: Tuesday, May 15, 2012

This activity offers CE credit for:

1. Physicians (CME)
2. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, May 15, 2013
Note: Credit Is No Longer Available

Faculty

Charles B. Nemeroff, MD, PhD  Professor and Chair Department of Psychiatry Mulva Clinic for the Neurosciences Director, Institute of Early Life Adversity Research Dell Medical School The University of Texas at Austin Austin, TX

Jeffrey A. Lieberman, MD  President, American Psyichiatric Association Lawrence C. Kolb Professor and Chairman, Department of Psychiatry College of Physicians and Surgeons, Columbia University Director, New York State Psychiatric Institute Psychiatrist-in-Chief at New York Presbyterian Hospital & Columbia University Medical Center New York, NY

---

Co-provided by

 

Statement of Need

An important paradigm shift has occurred toward early intervention in schizophrenia, beginning with the prodrome of the illness. In addition, the focus of treatment has expanded beyond psychotic symptoms to include key clinical dimensions (e.g., cognition deficits and negative symptoms) as critical targets.(1) Our current understanding of the etiology and pathophysiology of schizophrenia allows us to begin targeting several steps in its pathogenesis and to look beyond the ”dopamine hypothesis” of schizophrenia for answers. Drug development has been predicated on finding the “magic bullet” that effectively addresses all aspects of the psychopathology of schizophrenia. In contrast our newer understanding of its distinct psychopathologic domains allows us to develop specifically targeted treatments for individual symptom dimensions of schizophrenia, rather than a single treatment for many disparate symptoms.(2)

This neuroscienceCME Snack, a video interview with Jeffrey Lieberman, MD, yields interesting clinical insights into unmet needs, current treatments, directions for improvement, and emerging pharmacological and future management strategies in schizophrenia.

---

1. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacol. 2008;33(9);2061-2079. PMID: 18046305.
2. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010;122(1-3):1-23. PMID: 20655178.

Activity Goal

To challenge clinicians who treat individuals with schizophrenia to address remaining, unmet needs in clinical management of these patients and to describe emerging therapies.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Identify patients with schizophrenia who have unmet clinical needs, such as cognitive problems and negative symptoms, and modify treatment strategies to improve care.
• Define emerging trends and treatment targets in the psychopharmacology of schizophrenia.
• Improve early identification of individuals with schizophrenia to minimize the duration of untreated illness.

Financial Support

USF Health and CME Outfitters, LLC, gratefully acknowledge an educational grant from Sunovion Pharmaceuticals Inc. in support of this CE activity.

This educational activity is supported by an independent medical education grant from Shire.

USF Health and CME Outfitters, LLC, gratefully acknowledge an educational grant from Genentech in support of this CE activity.

Target Audience

Physicians and nonphysician health care professionals with an interest in schizophrenia

Credit Information

CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/test (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

USF Health and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of USF Health and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

Dr. Lieberman has disclosed that he receives grants/research support from Allon Therapeutics, F. Hoffmann-La Roche LTD, GlaxoSmithKline, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Sepracor Inc., and Targacept, Inc. He serves as a consultant to Bioline, GlaxoSmithKline, Intra-Cellular Therapies, Inc., Lilly USA, LLC, Pierre Fabre Laboratories, and PsychoGenics, Inc. He holds a patent from Repligen Corporation.

Dr. Nemeroff has disclosed that he receives grants/research support from the Agency for Healthcare Research and Quality (AHRQ) and the National Institutes of Health (NIH). He serves as a consultant to Takeda Pharmaceuticals North America, Inc., and Xhale, Inc. He serves on the advisory boards of the American Foundation for Suicide Prevention (AFSP), the Anxiety Disorders Association of America (ADAA), CeNeRx BioPharma, the National Alliance for Research on Schizophrenia and Depression (NARSAD), NovaDel Pharma, Inc., and PharmaNeuroBoost. He serves on the board of directors of the American Foundation for Suicide Prevention and NovaDel Pharma, Inc. He is a stockholder of CeNeRx BioPharma, Corcept Therapeutics, NovaDel Pharma, Inc., PharmaNeuroBoost, Reevax Pharmaceuticals LLC, and Xhale, Inc. His other financial Interests include CeNeRx BioPharma and PharmaNeuroBoost. He holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).

Disclosures were obtained from the planning committee members and are on file in the USF Health Office of Continuing Professional Development (OCPD) for review. Disclosures were obtained from the USF Health OCPD staff: Nothing to Disclose.

Tony Graham, MD (peer/content reviewer) has no disclosures to report.

Robert Kennedy (planning committee) has no disclosures to report.

Joy Leffler, MLA, NASW (planning committee) has no disclosures to report.

Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

USF Health, CME Outfitters, LLC, the faculty, Sunovion Pharmaceuticals, Shire Pharmaceuticals, and Genentech do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Equal Opportunity Statement: Events, activities, programs and facilities of the University of South Florida are available to all without regard to race, color, marital status, gender, sexual orientation, religion, national origin, disability, age, Vietnam or disabled veteran status as provided by law and in accordance with the university's respect for personal dignity.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).